Global Nasal Drug Delivery Technology Market Size & Trends Report Segmented by Dosage Form (Sprays, Drops/Liquids, Powders, Gels), Container (Pressurized, Non-pressurized), System (Multi-dose, Bi-dose, Unit-dose), Therapeutic Application (Rhinitis, Vaccination, Asthma), & Regional Forecast to 2031

Nasal delivery systems are a method of administering therapeutic agents through the nasal cavity to achieve local, systemic, or central nervous system effects. The nasal mucosa is very vascularized and has an extensive surface area, which means medication can be absorbed and begin to work quickly, bypassing first pass hepatic metabolism. There are several different types of nasal medicine including sprays, drops, powder, and gel medications, and there are also several different types of nasal delivery devices that provide for accurate doses of medication and ensure optimal location for the deposition of the medication into the body. Nasal delivery systems are widely used to treat conditions like allergic rhinitis, congestion, pain, hormone shortage, and increasingly for vaccines and nose-to-brain therapies targeting neurological disorders among others.

Non-invasive and patient-friendly delivery to propel market demand

Non-invasive and patient-friendly delivery is one of the key drivers of the nasal drug delivery technology market, as it directly addresses long-standing challenges associated with conventional drug administration routes. For example, nasal administration helps eliminate most of the issues associated with injectable therapies such as an injection requiring the use of a needle; help in decrease pain, anxiety, and risk of needle injury; this is especially valuable to pediatric, geriatric, and other populations with fear of needles, who may not adhere to treatment due to fear or discomfort. By eliminating the need for needles, nasal drug delivery improves patient compliance and acceptance, thereby enhancing overall therapeutic effectiveness.

The second major advantage of nasal drug delivery is that it is simple and easy to administer. Many nasal delivery devices, such as nasal sprays, are portable and can typically be administered without a trained healthcare professional. Hence, patients can self-administer their medications in their own homes and thereby reduce the number of times they visit hospitals or other healthcare facilities, thus reducing the overall costs of healthcare. The convenience of dosing intranasally can increase the likelihood that patients with chronic medical conditions like allergic rhinitis, migraines, or hormone deficiencies can consistently dose their medications and adhere to the prescribed treatment regimen long-term.

A fast-acting delivery method appeals to patients due to its rapid onset of effect. The nasal cavity is highly vascularized, enabling quick absorption into systemic circulation and, in some cases, direct transport to the central nervous system. This makes nasal delivery particularly valuable in acute situations, such as pain episodes, seizure clusters, or opioid overdose emergencies, where timely intervention is critical. Faster symptom relief enhances patient satisfaction and reinforces physician confidence in prescribing nasal formulations. In addition, nasal delivery avoids the first-pass hepatic metabolism that occurs when medicine is administered orally, potentially resulting in a greater bioavailability and lower dosage, compared to oral route of administration. Lower doses may decrease systemic side effects, contributing to a safer and more tolerable treatment experience.

The increased focus on patient-centric healthcare models and home-based treatment are likely to continue to accelerate the implementation of nasal drug delivery technologies. Healthcare systems and pharmaceutical companies are increasingly prioritizing drug-device combinations that enhance comfort, usability, and independence. Therefore, non-invasive, and patient-friendly delivery methods not only provide a better clinical outcome but also align with the shift taking place in the healthcare system, thereby being one of the key drivers of the growth of the nasal drug delivery technology market.

To learn more about this report, download the PDF brochure

Faster absorption and improved bioavailability are driving the market growth

The nasal drug delivery technology market is experiencing growth due to faster absorption and improved bioavailability leading to enhanced clinical and therapeutic outcomes compared to conventional oral and injectable routes. The nasal cavity has a rich blood supply with a considerable amount of total surface area receptive to absorption, resulting in rapid entry of the drug into systemic circulation. Rapid entry of the drug leads to a faster onset of action, which is particularly important with respect to acute conditions such as migraines, pain episodes, allergies, or emergency medical treatment; therefore, timely control of symptoms yields better patient outcomes.

A significant advantage with the nasal route of administration is that it bypasses first-pass metabolism in the liver. Once a drug is administered orally, a large percentage is metabolized in the liver prior to entry into systemic circulation, resulting in lower effective bioavailability. Therefore, for many orally administered drugs, high doses would be necessary because of the amount lost during hepatic metabolism. In contrast, by directly administering drugs via the nasal route, a greater proportion of the active drugs is preserved for systemic exposure. By allowing for greater systemic bioavailability through the nasal route, lower dosages are typically required for effective therapy. Lower dosages typically correspond with reduced systemic side effects and thus enhance safety and tolerability of treatment.

Nasal drug delivery has the potential to directly transport drugs from the nose to the brain using olfactory and trigeminal nerve pathways, which makes it a viable option for central nervous system medications as it allows some drugs to bypass the blood-brain barrier. Drugs can thus be delivered to the central nervous system at greater concentrations and more quickly than they could be if delivered by oral or intravenous methods. As a result, nasal drug delivery is becoming an increasingly important means by which new medications for neurological conditions and psychiatric conditions, as well as for specific types of pain, can be targeted quickly and effectively.

Advances in formulation technology, including new permeation-enhancing agents, new mucoadhesive polymers, and new nano-based delivery systems, have helped to improve the absorption of drugs from the nasal cavity and prolong their residence time in the nasal cavity, while also helping to overcome the physiological barriers presented by mucociliary clearance so that the uptake of drugs is more consistent and efficient.

Together, faster absorption and improved bioavailability of drugs increase the clinical value proposition for nasal drug delivery and provides greater incentive for pharmaceutical companies to invest in nasal drug delivery technologies, offer an expanded range of new therapeutic applications, and accelerate the rate of adoption of nasal drug delivery technologies in the market.

Growth strategies adopted by players to establish their foothold in the market

Players operating in this market are adopting various growth strategies such as new product launches and approvals, acquisitions, expansions, and strategic partnerships, agreements, and collaborations, to garner market share. For instance,

• In February 2026, Emergent BioSolutions received US FDA approval for a supplemental New Drug Application (sNDA) for new 6-count and 24-count multipack configurations of NARCAN Nasal Spray. The approval enhances distribution flexibility and cost-efficiency for high-volume partners, supporting broader access to this life-saving opioid overdose treatment
• In September 2025, Aptar Pharma entered an exclusive partnership with Dianosic to advance the Active Resorbable Intranasal Scaffold (ARIS) platform for chronic allergic rhinitis and chronic rhinosinusitis. The collaboration strengthens Aptar’s nasal drug delivery portfolio, supports long-acting local drug administration, and explores nose-to-brain applications in neuropsychiatric and neurodegenerative diseases
• In October 2024, Aptar Pharma acquired the device technology assets of SipNose Nasal Delivery Systems to expand its intranasal drug delivery portfolio. The acquisition strengthens Aptar’s nose-to-brain capabilities, enhances its patent portfolio, and supports innovation in liquid and dry powder nasal systems, particularly for CNS therapies
• In January 2024, Recipharm entered an exclusive license and collaboration agreement with Medspray and Resyca to develop soft mist nasal delivery devices using proprietary spray nozzle technology. The partnership strengthens turnkey nasal and inhalation solutions and aims to advance innovative soft mist platforms, including applications for fragile biologics such as mRNA vaccines
• In November 2023, Hovione expanded its nasal drug delivery capabilities through a partnership with IDC to develop innovative single-use and multidose nasal powder delivery devices. The collaboration strengthens Hovione’s integrated offering across APIs, formulation, manufacturing, and device design, supporting advanced applications such as mucosal vaccines and CNS therapies.

To learn more about this report, download the PDF brochure

Dosage Form Segment Outlook

Nasal sprays account for the largest market share of nasal drug delivery technology due to their extensive use in treating conditions such as allergic rhinitis and nasal congestion, administering hormonal therapies, and managing pain. Factors such as the simplicity with which sprays can be used, ability to accurately deliver metered doses to the patient, physician familiarity with the use of sprays, and availability of a large number of commercial products have contributed to the largest share of sprays in the market. Powders are expected to exhibit the fastest growth in this segment due to their superior stability, ability to accommodate biologics and peptides, and increasing application in nose-to-brain delivery and vaccine development. Additionally, powder formulations mostly do not require preservatives and improve drug stability, allowing them to be an attractive option for next-generation intranasal therapy.

Regional Outlook: North America expected to hold a major share in the nasal drug delivery technology market

North America holds the largest share of the nasal drug-delivery technology market. This is due to strong pharmaceutical innovation, widespread use of advanced drug -device combos, favourable regulatory pathways, and many large players operating in the region. The growth of the North American segment has benefited from high healthcare spending and increased demand for non-invasive treatments, especially in CNS areas and for emergency care. Asia Pacific is the fastest-growing region in the market, driven by expanding healthcare infrastructure, growing incidence of respiratory disease, expanding pharmaceutical production facilities and more investment in research and development for nasal delivery technologies in countries like China, India, and Japan.

Competitive Landscape Analysis

The global nasal drug delivery technology market is marked by the presence of established and emerging market players such as Johnson & Johnson (US); GSK plc (UK); Pfizer Inc. (US); AstraZeneca (UK); Novartis AG (Switzerland); Aptar (US); Becton, Dickinson and Company (US); OptiNose US, Inc. (US); Dr Reddys Laboratories Ltd (India); and Cadila Pharmaceuticals (India); among others. Some of the key strategies adopted by market players include new product launches and approvals, acquisitions, expansions, and strategic partnerships, agreements, and collaborations.

Get a sample report for competitive landscape analysis

Report Scope

Global Nasal Drug Delivery Technology Market Segmentation

This report by Medi-Tech Insights provides the size of the global nasal drug delivery technology market at the regional- and country-level from 2024 to 2031. The report further segments the market based on dosage form, container type, system type, therapeutic application, and end user.

Market Size & Forecast (2024-2031), By Dosage Form, USD Billion

• Sprays
• Drops & Liquids
• Powders
• Gels
• Other Dosage Forms

Market Size & Forecast (2024-2031), By Container Type, USD Billion

• Pressurized Containers
• Non-pressurized Containers

Market Size & Forecast (2024-2031), By System Type, USD Billion

• Multi-dose Systems
• Bi-dose Systems
• Unit-dose Systems

Market Size & Forecast (2024-2031), By Therapeutic Application, USD Billion

• Allergic and Non-allergic Rhinitis
• Nasal Congestion
• Vaccination
• Asthma
• Other Therapeutic Applications

Market Size & Forecast (2024-2031), By End User, USD Billion

• Hospitals
• Home Care
• Other End Users

Market Size & Forecast (2024-2031), By Region, USD Billion

• North America
  • US
  • Canada
• Europe
  • UK
  • Germany
  • France
  • Italy
  • Spain
  • Rest of Europe
• Asia Pacific
  • China
  • India
  • Japan
  • Rest of Asia Pacific
• Latin America
• Middle East & Africa

Related Reports:

Global Injectable Drug Delivery Market Report Segmented by Device Type (Conventional & Self-Injectables, Needle-free Injectors), Route of Administration (Intravenous, Subcutaneous, Intramuscular), Therapeutic Application, Formulation Packaging, Forecast to 2031

Global Drug Device Combination Products Market Size & Trends Report Segmented by Product (Transdermal Patches, Infusion Pumps, Inhalers), Application (CVDs, Diabetes, Respiratory Disorders, Oncology), End-user Analysis & Regional Forecast to 2031

ENT Devices Market (2026 – 2031) Size, Share & Trends Analysis Report By Product (Diagnostic ENT Devices, Surgical ENT Devices, Nasal Splints), End-user (ENT Clinics, Home Use), By Region (North America (U.S. & Canada), Europe, Asia Pacific) and Segment Forecast